Although whole grain consumption has been associated with a lower risk of cardiovascular disease incidence and mortality in the general population, little is known about the effect of whole grain and its components on cardiovascular risk and mortality in diabetic patients. In this prospective study, we followed 7822 US women with type 2 diabetes mellitus for up to 26 years to investigate intakes of whole grain and its components cereal fiber, bran, and germ in relation to all-cause and cardiovascular disease-specific mortality. Our results indicated that intakes of whole grain, especially its subcomponent bran, were inversely associated with all-cause and cardiovascular disease-specific mortality among women with type 2 diabetes mellitus. Low whole-grain intake may be considered an important modifiable risk factor for decreasing mortality and cardiovascular risk in persons with diabetes mellitus. See p 2162.
Peripartum Cardiomyopathy as a Part of Familial Dilated Cardiomyopathy
Anecdotal cases with familial clustering of peripartum cardiomyopathy (PPCM) or joint occurrence of PPCM and idiopathic dilated cardiomyopathy (DCM) within families have been reported. We performed the first systematic study of the relation between PPCM and familial DCM. In a substantial number of DCM families (5/90), cases of PPCM were found, and more important, previously undiagnosed cases of DCM were identified in all 3 families of PPCM patients who did not show a full recovery. Moreover, our results support the genetic nature of the disease in 1 DCM family with PPCM: We identified a mutation in the gene encoding cardiac troponin C (TNNC1). We therefore conclude that PPCM can be a manifestation of familial DCM. Obviously, further research is needed to confirm these observations in a larger series of patients. However, our findings already have several clinical implications and may change clinical practice and thinking about PPCM. Because PPCM can be the first manifestation of familial DCM, we recommend presymptomatic cardiological screening for covert DCM in first-degree family members of PPCM patients without recovery of left ventricular function and dimensions. Second, cardiological screening during pregnancy should be considered for healthy women (ie, without proven previous signs of DCM) who are first-degree family members of familial DCM patients and this should be extended into the puerperium. See p 2169.
Rare Variant Mutations in Pregnancy-Associated or Peripartum Cardiomyopathy
The term peripartum cardiomyopathy (PPCM) describes dilated cardiomyopathy (DCM) without known cause that occurs during the last month of pregnancy to 5 months postpartum. A related term, pregnancy-associated cardiomyopathy (PACM), refers to DCM onset earlier in pregnancy. Despite multiple studies focused on inflammatory, immunologic, and environmental causes, no unifying hypothesis has been proven. An alternative hypothesis is that PPCM and PACM result from a genetic cause. In an effort to identify preliminary support for this hypothesis, a systematic search of a large database, collected for family-based genetic DCM studies over the past 15 years, was undertaken for cases associated with pregnancy and the postpartum period. When cases were identified, available clinical and molecular genetic data were analyzed. Of the 4110 women from 520 pedigrees in the Familial Dilated Cardiomyopathy Research Project database, 45 cases of PPCM/PACM were identified, 23 with familial clustering, of which 19 had been resequenced for known DCM genes. Six of these 19 carried mutations in genes shown previously to be associated with DCM. These data indicate that PPCM/PACM may have a genetic basis in some cases. Thus, we recommend that clinicians caring for PPCM/PACM patients be aware that PPCM/PACM may have a genetic basis and that guidelines for evaluation of genetic cardiomyopathy be followed. Specifically, this includes clinical screening (family history, medical history, examination, ECG, echocardiography) of the patient and her first-degree relatives. Genetic counseling, including reproductive risk counseling about PPCM/PACM, is recommended, in addition to consideration of genetic testing. See p 2176.
Acute Kidney Injury and Cardiovascular Outcomes in Acute Severe Hypertension
Little is known about the association between kidney dysfunction and outcome in acute severe hypertension. Using data from the Studying the Treatment of Acute Hypertension (STAT) registry, this study examined the associations between both acute kidney injury and chronic kidney disease among patients with acute severe hypertension. On admission, 79% of the cohort had at least mild chronic kidney disease and were subject to a greater risk of heart failure, non-ST-elevation myocardial infarction, and acute kidney injury. Not surprisingly, acute kidney injury patients were also at greater risk of heart failure, cardiac arrest, and mortality at 90 days. However, quite notable is the fact that any acute loss of estimated glomerular filtration rate during hospitalization was independently associated with an increased risk of death (odds ratio, 1.05; Pϭ0.03 per 10-mL/min decline). This study strongly supports the clinical need for early and frequent monitoring of kidney function to facilitate risk stratification among those admitted with acute severe hypertension. It also strongly supports research on whether treatment aimed at preventing or mitigating the severity of the acute kidney injury will lower the risk. The clinician should therefore be aware that patients with even a subtle decline in kidney function after admission are at higher risk for other cardiovascular events and tailor their therapy on a case-by-case basis. See p 2183.
Smooth Muscle Cells Orchestrate the Endothelial Cell Response to Flow and Injury
Local delivery of antiproliferative drugs limits restenosis but may increase thrombosis even late after intervention. Device implantation and drug administration can synergistically induce endothelial dysfunction and delay recovery, impairing vasoreactivity, enhancing platelet aggregation, and elevating tissue factor expression. As stents are placed in increasingly complex geometries in the face of local and systemic disease, in the presence of clot and inflammation, a complex spectrum of issues must be considered that can no longer be intuited or dissected from in vivo experiments. We developed a model flow system examining signaling in vascular cells under controlled physiological flows. Our data demonstrate a profound difference in endothelial cell biology in the presence and absence of 2155
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Original Research Put Into Perspective for the Practicing Clinician Volume 121 Ⅲ Number 20 Ⅲ May 25, 2010 smooth muscle cells and suggest a far more sophisticated regulatory interaction between alterations in hemodynamics from above and vessel wall from below than classically appreciated. Similar to the triad that governs venous thrombosis, we now observe that signaling within vascular endothelial and smooth muscle cells is set by the biochemical milieu established by blood, local flow disruptions, and the state of the wall and its cells. The relative effects of the stent itself on the cells may explain the enhanced sensitivity of the endothelium after local delivery of agents that interfere with mammalian target of rapamycin signaling, placing vessels at risk of thrombosis even late after the initial treatment. Flow models with multiple cell systems bring us back to Virchow and forward into the era of complex vascular interventions and emerging concepts in vascular biology. See p 2192.
Prelamin A Acts to Accelerate Smooth Muscle Cell Senescence and Is a Novel Biomarker of Human Vascular Aging
Age is the strongest risk factor for the development of vascular decline and associated mortality. Therefore, understanding the mechanisms of cell-specific forms of aging may lead to the development of novel targets for therapeutic intervention. Children with the genetic condition Hutchison-Gilford progeria syndrome develop tissue-specific symptoms of premature aging and die of myocardial infarction within the second decade. This is due to rapid vascular decline caused by the severe loss and dysfunction of vascular smooth muscle cells (VSMCs). Hutchison-Gilford progeria syndrome is caused by the toxic accumulation of a mutant form of the nuclear lamina protein lamin A. This mutant protein, called progerin, acts to deregulate mitosis and DNA damage signaling, leading to premature cell death and senescence. In this study, we show that VSMC aging and disease in the normal population are associated with the abnormal accumulation of prelamin A, which, like progerin, is an unprocessed form of lamin A. In normal aging, the accumulation of prelamin A is caused in part by the downregulation of the processing enzyme FACE1 by oxidative stress. Prelamin A accumulation accelerates VSMC DNA damage and senescence and may also impinge on VSMC phenotype to promote age-associated vascular pathologies such as calcification. Importantly, some of the toxic effects of prelamin A are thought to be due to permanent farnesylation, suggesting that drugs that interfere with this pathway, such as statins, may be useful for the treatment of age-related vascular dysfunction. See p 2200.
Mobilized Human Hematopoietic Stem/Progenitor Cells Promote Kidney Repair After Ischemia/Reperfusion Injury
Acute kidney injury, formerly known as acute tubular necrosis, has reached epidemic proportions. It is a harbinger for chronic kidney disease, end-stage kidney disease, cardiovascular events, and untimely death. Despite this, other than supportive management, there are no active therapeutic strategies that promote repair and regeneration. In this article, Li and colleagues identify a promising new strategy for the treatment of acute kidney injury using cellular therapy. Human stem cells were mobilized from healthy donors and purified from peripheral blood. They were infused into mice with acute kidney injury. The human stem cells trafficked to the kidney, where they orchestrated microvascular repair. The consequence of this microvascular repair was enhanced animal survival and prompt resolution of organ failure. One month after injury, the propensity to develop organ fibrosis, a characteristic of chronic kidney disease, was significantly diminished. The kidney repair prompted by human stem cells manifested as enhanced proliferation in both the microvascular and nephron compartments of the injured organ rather than replacement of kidney cells. These compelling studies in mice highlight the urgent need for new therapies focused on vascular repair/regeneration and raise the possibility that donor human stem cells might be indicated prophylactically in patients at high risk of acute kidney injury. See p 2211.
